


a

B001

Characteristics	
Age	53
Stage at diagnosis	non-IV
ECOG	1
Metastatic organ	Lung, Liver, bone
No. of previous lines of therapy	5
Drugs that have been used	Anthracyclines, paclitaxel, carboplatin, vinorelbine, capecitabine, gemcitabine, tegafur and apatinib
IHC results	AR (+, 90%), CD8 (+, 25%) , FOXC1 (-)

**b**

B002

Characteristics	
Age	48
Stage at diagnosis	non-IV
ECOG	1
Metastatic organ	Lung
No. of previous lines of therapy	5
Drugs that have been used	Anthracyclines, paclitaxel, carboplatin, vinorelbine, gemcitabine, capecitabine
IHC results	AR3(+, 90%), CD8 (-), FOXC1 (-)
SCNV	FGFR1 amplification




Figure S6. Patients benefited from other targets except for anti-AR plus anti-CDK 4/6 in arm B

(a) One patient with AR (+) and CD8 (+, 25%) benefited from anti-PD-1 therapy after progressed from therapy of arm B; (b) One patient with FGFR1 amplification benefited from anlotinib therapy after progressed from therapy of arm B

Abbreviations: PR, partial response; SD, stable disease; PD, progressive disease; ECOG, Eastern Cooperative Oncology Group.